bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.10.20.683431

A New anticancer substance from cancer cell apoptosis. CSS (Cancer cell Suicide Substance) production in culture.

Abstract

It is well-known that the cells die when a cancer cell line is continuously cultured without passage, even though it was kept in a fresh medium. However, none of this phenomenons decisive causes and mechanism(s) have been elucidated yet. After the cancer cell death, the medium exserted cytocidality. This cancer cell death (e.g., spontaneous, apoptosis, programmed) was found to be caused by only one kind of cytocidal substance (MW<1kDa) (named CSS) produced from the cells own component(s) by the cells themselves. CSS mammalian specifically by cancer cell lines but not nontumor cell lines and the CSS exerted cytocidality against other cell lines and vice versa regardless of species in mammalian. In vivo, CSS showed a significant life-prolonging effect without any adverse event. An established cell line derived from human renal cell carcinoma (HRC23) was used in this study as CSS was found and characterized by this cell line first. HighlightsO_LIOnly one kind of low molecular substance exerting cytocidality was found only in a medium after cancer cells death in the culture but not in non-tumor cell lines one. C_LIO_LIThe cytocidal substance (named CSS: cancer cell suicide substance) was a small molecule (MW<1kDa) with a slightly positively charged highly hydrophilic character. C_LIO_LICSS was produced regardless of extracellular nutritional condition, even in glucose-free HBSS (Nutrition-Free Method.) C_LIO_LICSS exserted cytocidality against other cancer cell lines irrespective of the histological patterns and the species of mammalian cells and vice versa. C_LIO_LICSS can be considered as a direct and critical substance produced from cell component(s) themselves by the cancer cells themselves. C_LIO_LIProduction of CSS was specific for cancer cells. This clear functional difference between cancer and nontumor cells should be meaningful embryologically. C_LIO_LIIn vivo, CSS showed complete anti-metastasis during administration period against Lewis Lung Carcinoma (LLC) transplanted mouse without any adverse event. CSS may have high potential as a new type of cancer therapy drug. C_LI In shortThis study is so simple, absolutely reproducible and anyone can reproduce this study with an easy basic method. A critical substance CSS (cancer cell suicide substance) of spontaneous cancer cell death was found in a medium after the cancer cells had been dead. Only one kind of small-size substance with MW<1kDa with a highly water-soluble and positively charged character is made only from cell own component(s) itself by the cells themselves. Even in a nutrition-free physiologically balanced salt solution, CSS was produced regardless of extracellular nutritional condition. Only cancer cell lines produced CSS, but not by non-tumor cell lines. CSS exserted cytocidality against other histologically different patterns of cancer cell lines regardless of species and vice versa. The anticancer effect of HRC23 produced CSS in vivo against mouse LLC (Lewis Lung Carcinoma)-transplanted mice showed a clear life-prolonging effect without any adverse event. Thus, CSS may have the possibility to be a cancer therapy drug. And, in view of embryologically, this clear difference of CSS production between cancer cells and nontumor cells will be important event.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tajima, T., Kondo, Y.. 2025-10-21. A New anticancer substance from cancer cell apoptosis. CSS (Cancer cell Suicide Substance) production in culture.. https://doi.org/10.1101/2025.10.20.683431

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗